Marianne Mertens
Managing Director at Booster Therapeutics
Greater Munich Metropolitan Area
Overview
Work Experience
Partner
2021 - Current
Apollo Health Ventures is an early-stage investment firm dedicated to transforming breakthrough scientific discoveries into clinical advancements by creating life science companies centered on innovative therapeutic technologies. With over $300 million under management, Apollo focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as dementia, heart disease, and cancer, aiming to extend healthy human lifespan. The firm partners with scientists and entrepreneurs to build innovative companies, leveraging a hypothesis-driven approach to venture creation and development.
Managing Director and Board Director
2022
Booster is developing first-in-class proteasome enhancers to treat multiple diseases.
Board Director
2023
Haya is dedicated to developing advanced RNA-targeted therapies, particularly focusing on long non-coding RNAs, to treat fibrotic diseases at their core.
Board Observer
2022
Auron is developing life-saving therapies by targeting cell-state plasticity to identify the root causes of disease.
Board Director
2022
Cleara progresses a pipeline of compounds that are capable of selectively eliminating senescent and senescent-like cancer cells.
Board Observer
2023
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases.
Principal
2018 - 2021
Since 1998, Wellington Partners has been a leading European Venture Capital firm investing in early- and growth-stage Life Science companies. Led Wellington's investments in - Confo Therapeutics - Imcheck Therapeutics www.wellington-partners.com
Board Director
2019 - 2021
Confo utilizes pioneering G protein-coupled receptor (GPCR) technology to build up a portfolio of first-in-class programs addressing difficult-to-drug disease targets in neurology and beyond. The company entered a global licensing agreement with Eli Lilly valued at 630 million USD.
Board Observer
2019 - 2021
UroMems is developing an electrical artificial urinary sphincter (eAUS) system for treatment of medium to severe stress urinary incontinence.
Board Observer
2019 - 2021
SNIPR BIOME develops CRISPR-based drug candidates for infections and microbiome engineering in auto-immune and malignant disorders.
Education
Dr. rer. nat., Biotechnology
2010 - 2013